Does Semaglutide Cause Liver Issues — and What Should You Do?

You've read something alarming about semaglutide and your liver, here's the full picture

It's a reasonable thing to worry about. You come across a forum post, or a friend mentions liver enzymes, and suddenly you want to know exactly what this medicine is doing inside your body. That instinct is worth following up properly.

The evidence gathered so far points largely in a reassuring direction. The STEP clinical trials, which studied semaglutide 2.4mg in thousands of adults over 68 weeks, reported reductions in liver fat content and improvements in liver inflammation markers alongside weight loss. Because excess weight is one of the main drivers of metabolic-associated steatohepatitis (MASH), it is plausible (and now clinically supported) that the medicine that reduces weight also reduces the liver burden that goes with it.

The strongest signal came on 3 July 2026, when the MHRA granted conditional approval for semaglutide (Wegovy) specifically for adults with MASH and moderate-to-advanced liver fibrosis, making it the first GLP-1 medicine to receive that indication in the UK. You can read the announcement directly on GOV.UK's news release on semaglutide's MASH approval. That approval does not mean semaglutide cures liver disease, or that it is suitable for every liver condition, conditional approvals come with ongoing requirements to gather further data. But it means regulators looked at the evidence and judged benefit to outweigh risk in a specific liver-disease population.

For a broader overview of how Wegovy works and what it is licensed for in the UK, the Wegovy treatment page sets this out clearly.

Can semaglutide raise liver enzymes, and when is that a concern?

Liver enzymes (ALT and AST in particular) are markers of liver cell stress. Raised levels do not automatically mean liver damage; they can reflect perfectly ordinary things, including weight loss itself (fat mobilisation can temporarily bump enzyme levels) or an unrelated infection.

Post-marketing safety data has captured a small number of cases where people on semaglutide experienced liver enzyme elevations, and a handful of more serious reports. Because Wegovy carries a Black Triangle (▼) designation, every suspected reaction must be reported to the MHRA, which keeps the safety picture under continuous review. The NHS patient-level information on semaglutide recommends telling your doctor or pharmacist if you notice yellowing of the skin or eyes, dark urine, or persistent upper abdominal discomfort, these are signs the liver should be checked promptly.

The detail on what to watch for is set out in the NHS semaglutide medicines page, which is updated as new evidence emerges. If your results include elevated enzymes and you are already on semaglutide, the right step is a conversation with your GP, not stopping the medicine without clinical advice. For more on the specific question of enzyme levels, the page on whether semaglutide can cause elevated liver enzymes goes deeper.

If anything feels urgent (severe stomach pain, jaundice, dark urine) seek medical help the same day rather than waiting for a routine appointment.

What's still uncertain, and who should take extra care

Science does not work in neat before-and-after snapshots. Even with the MASH approval and trial data showing improvements, some questions remain open.

Most clinical trial populations had specific characteristics, typically obesity without advanced cirrhosis. People with decompensated liver disease, severe fibrosis, or concurrent conditions were often excluded. Whether semaglutide carries the same benefit-to-risk profile in those groups is not yet fully established.

There is also the practical question of drug interactions. People with liver conditions are often on other medicines, some of which are processed by the same metabolic pathways. A prescriber needs to know your full medication list, not just the headline diagnosis. For the same reason, anyone considering semaglutide after previous liver-related treatment should discuss evidence of their current health status with the clinician reviewing their case, and if you want a thorough look at whether semaglutide causes liver damage, that page brings together the current evidence in one place.

Pregnancy is a separate consideration. Semaglutide is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive, and if you are weighing up your options around fertility or conception, the page on getting pregnant on Wegovy covers what the evidence says and what steps to take if your situation changes. The Wegovy and pregnancy page covers what is known and what to do if your situation changes. If you are worried about cardiovascular health alongside liver concerns, the semaglutide and heart issues page addresses that evidence directly.

The bottom line is that semaglutide appears to be liver-neutral at worst and liver-beneficial in several well-studied populations. But your liver health is personal, and no content page replaces a clinician who can read your results and your history side by side.

Starting semaglutide safely through a regulated UK pharmacy

If you are considering Wegovy and you have a liver condition, or simply want to know whether treatment is right for you, the process at nume is straightforward. Your consultation is reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician reads your answers, not software. If you order before noon on a working day and are clinically approved, your treatment is dispatched the same day and arrives with DPD the next working day in plain packaging.

That review includes questions about medical history, existing conditions and current medicines, precisely because situations like pre-existing liver disease matter to clinical decision-making. The clinical team operates within a GPhC-registered pharmacy, dispensing through the licensed UK supply chain only. You can verify the pharmacy's registration number (9012878) on the GPhC pharmacy register directly.

If you have further questions before you start, the FAQs page covers the most common queries, or you can get in touch with the team directly. When you are ready, start your free consultation and a prescriber will assess your situation properly.